NEUP vs. ALVR, SCYX, IRD, LVTX, COEP, OSTX, XFOR, NRXP, AKTX, and SRZN
Should you be buying Neuphoria Therapeutics Inc. - Common Stock stock or one of its competitors? The main competitors of Neuphoria Therapeutics Inc. - Common Stock include AlloVir (ALVR), SCYNEXIS (SCYX), Opus Genetics (IRD), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), OS Therapies (OSTX), X4 Pharmaceuticals (XFOR), NRx Pharmaceuticals (NRXP), Akari Therapeutics (AKTX), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.
Neuphoria Therapeutics Inc. - Common Stock vs.
Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
Neuphoria Therapeutics Inc. - Common Stock has higher revenue and earnings than AlloVir.
In the previous week, Neuphoria Therapeutics Inc. - Common Stock had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for Neuphoria Therapeutics Inc. - Common Stock and 0 mentions for AlloVir. Neuphoria Therapeutics Inc. - Common Stock's average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.
15.9% of Neuphoria Therapeutics Inc. - Common Stock shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 0.7% of Neuphoria Therapeutics Inc. - Common Stock shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Neuphoria Therapeutics Inc. - Common Stock presently has a consensus price target of $21.00, indicating a potential upside of 308.56%. Given Neuphoria Therapeutics Inc. - Common Stock's stronger consensus rating and higher probable upside, equities analysts clearly believe Neuphoria Therapeutics Inc. - Common Stock is more favorable than AlloVir.
AlloVir received 26 more outperform votes than Neuphoria Therapeutics Inc. - Common Stock when rated by MarketBeat users. However, 100.00% of users gave Neuphoria Therapeutics Inc. - Common Stock an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
Neuphoria Therapeutics Inc. - Common Stock has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Neuphoria Therapeutics Inc. - Common Stock's return on equity of 0.00% beat AlloVir's return on equity.
Summary
Neuphoria Therapeutics Inc. - Common Stock beats AlloVir on 9 of the 13 factors compared between the two stocks.
Get Neuphoria Therapeutics Inc. - Common Stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuphoria Therapeutics Inc. - Common Stock Competitors List
Related Companies and Tools
This page (NASDAQ:NEUP) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy NEUP Stock Free NEUP Stock Alerts